These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 8514401)

  • 1. Effects of strain variation, serotype, and structural modification on kinetics for activation and binding of C3 to Cryptococcus neoformans.
    Young BJ; Kozel TR
    Infect Immun; 1993 Jul; 61(7):2966-72. PubMed ID: 8514401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation and binding of opsonic fragments of C3 on encapsulated Cryptococcus neoformans by using an alternative complement pathway reconstituted from six isolated proteins.
    Kozel TR; Wilson MA; Pfrommer GS; Schlageter AM
    Infect Immun; 1989 Jul; 57(7):1922-7. PubMed ID: 2525113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analysis of the amplification phase for activation and binding of C3 to encapsulated and nonencapsulated Cryptococcus neoformans.
    Kozel TR; Wilson MA; Welch WH
    Infect Immun; 1992 Aug; 60(8):3122-7. PubMed ID: 1639481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contribution of antibody in normal human serum to early deposition of C3 onto encapsulated and nonencapsulated Cryptococcus neoformans.
    Wilson MA; Kozel TR
    Infect Immun; 1992 Mar; 60(3):754-61. PubMed ID: 1541548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in Cryptococcus neoformans capsular polysaccharide structure influence assembly of alternative complement pathway C3 convertase on fungal surfaces.
    Washburn RG; Bryant-Varela BJ; Julian NC; Bennett JE
    Mol Immunol; 1991; 28(4-5):465-70. PubMed ID: 2062324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of anticapsular monoclonal antibodies that regulate activation of the complement system by the Cryptococcus neoformans capsule.
    Kozel TR; deJong BC; Grinsell MM; MacGill RS; Wall KK
    Infect Immun; 1998 Apr; 66(4):1538-46. PubMed ID: 9529079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early events in initiation of alternative complement pathway activation by the capsule of Cryptococcus neoformans.
    Kozel TR; Wilson MA; Murphy JW
    Infect Immun; 1991 Sep; 59(9):3101-10. PubMed ID: 1831795
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of the complement system by Cryptococcus neoformans leads to binding of iC3b to the yeast.
    Kozel TR; Pfrommer GS
    Infect Immun; 1986 Apr; 52(1):1-5. PubMed ID: 3514450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antigenic and biological characteristics of mutant strains of Cryptococcus neoformans lacking capsular O acetylation or xylosyl side chains.
    Kozel TR; Levitz SM; Dromer F; Gates MA; Thorkildson P; Janbon G
    Infect Immun; 2003 May; 71(5):2868-75. PubMed ID: 12704160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological correlates of capsular (quellung) reactions of Cryptococcus neoformans.
    MacGill TC; MacGill RS; Casadevall A; Kozel TR
    J Immunol; 2000 May; 164(9):4835-42. PubMed ID: 10779792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secretion of the C3 component of complement by peritoneal cells cultured with encapsulated Cryptococcus neoformans.
    Blackstock R; Murphy JW
    Infect Immun; 1997 Oct; 65(10):4114-21. PubMed ID: 9317016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of the capsule in phagocytosis of Cryptococcus neoformans.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Rev Infect Dis; 1988; 10 Suppl 2():S436-9. PubMed ID: 3055212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo complement activation and binding of C3 to encapsulated Cryptococcus neoformans.
    Truelsen K; Young T; Kozel TR
    Infect Immun; 1992 Sep; 60(9):3937-9. PubMed ID: 1500204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential localization of complement component 3 within the capsular matrix of Cryptococcus neoformans.
    Gates MA; Kozel TR
    Infect Immun; 2006 Jun; 74(6):3096-106. PubMed ID: 16714537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Strain variation in phagocytosis of Cryptococcus neoformans: dissociation of susceptibility to phagocytosis from activation and binding of opsonic fragments of C3.
    Kozel TR; Pfrommer GS; Guerlain AS; Highison BA; Highison GJ
    Infect Immun; 1988 Nov; 56(11):2794-800. PubMed ID: 3049374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure and biological activities of acapsular Cryptococcus neoformans 602 complemented with the CAP64 gene.
    Chang YC; Cherniak R; Kozel TR; Granger DL; Morris LC; Weinhold LC; Kwon-Chung KJ
    Infect Immun; 1997 May; 65(5):1584-92. PubMed ID: 9125534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Binding of cryptococcal polysaccharide to Cryptococcus neoformans.
    Kozel TR; Hermerath CA
    Infect Immun; 1984 Mar; 43(3):879-86. PubMed ID: 6365785
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation and binding of C3 by Candida albicans.
    Kozel TR; Brown RR; Pfrommer GS
    Infect Immun; 1987 Aug; 55(8):1890-4. PubMed ID: 3301679
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accelerated decay of C3b to iC3b when C3b is bound to the Cryptococcus neoformans capsule.
    Pfrommer GS; Dickens SM; Wilson MA; Young BJ; Kozel TR
    Infect Immun; 1993 Oct; 61(10):4360-6. PubMed ID: 8406826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bivalency is required for anticapsular monoclonal antibodies to optimally suppress activation of the alternative complement pathway by the Cryptococcus neoformans capsule.
    Kozel TR; MacGill RS; Wall KK
    Infect Immun; 1998 Apr; 66(4):1547-53. PubMed ID: 9529080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.